Therefore, for a more comprehensive mechanistic-based evaluation of the drug, it is advantageous to profile circulating tumour cells for MCT1 and MCT4 expression to elucidate the association between these transporters and AZD3965 sensitivity or resistance. This evidence concerns the gene SLC16A4 and neoplasm.